- Sanofi terminates oral STAT6 degrader (SAR448272) program and discontinues Phase 1 clinical trial
- Loss of collaboration asset removes future milestone and royalty potential for this candidate
Bearish AI Sentiment (-6.5 / 10)
Signal #119151 · SEC 8-K
$NRIX SEC Filing Alert & Real-Time AI Stock Impact Analysis
Public T0 SEO entry. Full AI score & bullets unlock after 4 hours (VIP: instant).
FAQ: $NRIX filing catalyst
Why did $NRIX trigger an AI stock catalyst alert?
$NRIX triggered a Stock Catalyst AI alert on 2026-11-03 00:00:00 UTC for a SEC 8-K filing (AI Score: -6.5/10). Headline: Nurix Therapeutics: Sanofi Discontinues Phase 1 Trial and Terminates SAR448272 Program. Key points: - Sanofi terminates oral STAT6 degrader (SAR448272) program and discontinues Phase 1 clinical trial - Loss of collaboration asset removes future milestone and royalty potential for this candidate
How did $NRIX stock react after the SEC filing?
After the SEC 8-K for $NRIX, observed market reaction: T0 price $25.82. Past moves do not guarantee future results.
Where can I get real-time $NRIX SEC filing alerts?
Stock Catalyst AI pushes real-time SEC 8-K alerts for $NRIX via Telegram and the VIP Web Terminal from €10/month.